Approved IBS drug Bentyl may help overcome chemo-resistant prostate cancer
A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate cancer in mice when given in tandem with chemotherapy, a new study shows.
A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate cancer in mice when given in tandem with chemotherapy, a new study shows.
Ionis Pharmaceuticals’ investigational treatment for hereditary angioedema (HAE) has hit the primary endpoint of a phase 3 trial, allowing the biotech to ready its approval application to the FDA.
The FDA has granted a clearance to its first prescription medical device to help treat low bone density, with a wearable vibrating belt designed for postmenopausal women.
Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.
Pharvaris’ preventative oral medicine for hereditary angioedema (HAE) has had its remaining clinical hold lifted by the FDA weeks after the treatment proved its worth in a phase 2 study.
Spinal cord stimulation has been available as a chronic pain treatment for decades, but even now, Medtronic—which was the first to make the implants commercially available in the late 1960s—is still improving on the technology.
Leadership at the FDA and the Centers for Medicare and Medicaid Services issued a joint statement to reiterate plans to increase the federal oversight of lab-developed tests, commonly known as LDTs.
Kyverna has nabbed another FDA fast-track designation for its lead asset, adding further momentum to its IPO roadshow days after declaring plans to go public.
The FDA this week published a safety notice alerting patients and healthcare providers to possible risks linked to certain shoulder joint replacement implants.
With Medtronic and Johnson & Johnson securing international approvals in the nascent domain of pulsed field ablation, Abbott is looking to join the party with its own approach for treating atrial fibrillation and other arrhythmias.